Article (Scientific journals)
Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.
Sobotta, Svantje; Raue, Andreas; Huang, Xiaoyun et al.
2017In Frontiers in Physiology, 8, p. 775
Peer Reviewed verified by ORBi


Full Text
Publisher postprint (4.21 MB)

All documents in ORBilu are protected by a user license.

Send to


Keywords :
IL-6; acute phase response; mathematical modeling; primary hepatocytes; ruxolitinib
Abstract :
[en] IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential equations (ODE) and the model parameters were estimated by a maximum likelihood approach, whereas identifiability of the dynamic model parameters was ensured by the Profile Likelihood. Using model simulations coupled with experimental validation we could optimize the long-term impact of the JAK-inhibitor Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted doses and timing of treatments helps to improve the reduction of inflammatory APP gene expression in primary mouse hepatocytes close to levels observed during regenerative conditions. The concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes. Thus, combining quantitative data generation with mathematical modeling suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Sobotta, Svantje
Raue, Andreas
Huang, Xiaoyun
Vanlier, Joep
Junger, Anja
Bohl, Sebastian
Albrecht, Ute
Hahnel, Maximilian J.
Wolf, Stephanie
Mueller, Nikola S.
D'Alessandro, Lorenza A.
Mueller-Bohl, Stephanie
Boehm, Martin E.
LUCARELLI, Philippe ;  University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit
Bonefas, Sandra
Damm, Georg
Seehofer, Daniel
Lehmann, Wolf D.
Rose-John, Stefan
van der Hoeven, Frank
Gretz, Norbert
Theis, Fabian J.
Ehlting, Christian
Bode, Johannes G.
Timmer, Jens
Schilling, Marcel
Klingmuller, Ursula
More authors (17 more) Less
External co-authors :
Language :
Title :
Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.
Publication date :
Journal title :
Frontiers in Physiology
Publisher :
Frontiers Media S.A., Switzerland
Volume :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBilu :
since 25 October 2017


Number of views
67 (1 by Unilu)
Number of downloads
181 (0 by Unilu)

Scopus citations®
Scopus citations®
without self-citations
WoS citations


Similar publications

Contact ORBilu